Skip to content

Study on monoamine neurotransmitters for hyperbaric oxygen therapy for depression after stroke

Study on monoamine neurotransmitters for hyperbaric oxygen therapy for depression after stroke

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100053522
Enrollment
Unknown
Registered
2021-11-24
Start date
2021-12-16
Completion date
Unknown
Last updated
2022-10-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral vascular disease

Interventions

Control group:Pseudo hyperbaric oxygen stimulation

Sponsors

Ningbo Kangning Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Those who meet the definition of stroke by the World Health Organization (WTO); 2. Diagnosed with cerebral hemorrhage, cerebral infarction or cerebral small vessel disease by brain CT or MRI and other imaging data, aged 30-80 years; 3. Meet the DSM-5 symptom criteria for depression; 4. The total score of 17 items of HAMD scale is more than 7 points; 5. Clear consciousness, stable vital signs, no aphasia and other comprehension and expression barriers and serious intellectual impairment; 6. Inform the family members of various risks that the patient may have during the research and treatment process. The family members are aware of the above risks, agree to be enrolled and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Severe heart, lung, kidney, epilepsy, glaucoma, substance dependence and other diseases; 2. Those with contraindications to hyperbaric oxygen; 3. Termination of treatment due to changes in condition.

Design outcomes

Primary

MeasureTime frame
Hamilton Depression Scale;

Secondary

MeasureTime frame
Montreal Cognitive Assessment;Mini-mental State Examination;Hachinski Ischemic Scale;Barthel Index Scale;Pittsburgh Sleep Quality Index Scale;Neuropsychiatric Inventory, NPI;Electroencephalophysiological indicators;Functional near-infrared spectroscopy;Neurotransmitter power;Polysomnography;

Countries

China

Contacts

Public ContactZhao Yuanzhi

Ningbo Kangning Hospital

1225316340@qq.com+86 15888125689

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 25, 2026